• What is MLL-MLLT3?
  • MLL-MLLT3 in Acute Myeloid Leukemia
  • MLL-MLLT3 Fusion
  • Clinical Trials

MLL-MLLT3

Lysine (K)-specific methyltransferase 2A, a gene with the official symbol KMT2A, is commonly known as MLL. MLL encodes for a protein involved in regulating gene expression during early development and hematopoiesis (Gene 2013). In cancer, rearrangements involving MLL have been observed in AML and ALL. Its role is also being investigated in gastric, colorectal, and other cancers.

Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3 (MLLT3) is a gene that encodes for a protein involved in cell growth and maintenance (GenAtlas 2013). In cancer, rearrangements involving MLLT3 have been observed in AML. MLLT3 is also known as AF9.

The MLL-MLLT3 fusion has been observed in AML and B lymphoblastic leukemia/lymphoma (Takachi et al. 2011; Metzler et al. 2004​).

Related Pathways

Contributors: Adam Seegmiller, M.D., Ph.D., Madan Jagasia, M.B.B.S., M.S.

Suggested Citation: Seegmiller, A., M. Jagasia. 2015. MLL-MLLT3. My Cancer Genome https://www.padiracinnovation.org/content/disease/acute-myeloid-leukemia/mll-mllt3/?tab=0 (Updated December 4).

Last Updated: December 4, 2015

MLL-MLLT3 Fusion Gene in Acute Myeloid Leukemia

MLL-MLLT3 is one of several 11q rearrangements observed in AML; 11q arrangements occur with a frequency of about 1% in AML (Grimwade et al. 2010). The MLL-MLLT3 fusion gene, t(9;11)(p22;q23), results in a protein that prevents normal maturation of hematopoietic cells (Mueller et al. 2009). However, additional mutations are likely required for leukemogenesis (Pession et al. 2003). MLL-MLLT3 fusion genes fall into class II of the “two-hit” theory of leukemogenesis (Naoe and Kiyoi 2013). The official symbol for MLL is KMT2A.​

​​​​

Contributors: Adam Seegmiller, M.D., Ph.D., Madan Jagasia, M.B.B.S., M.S., Scott Wheeler, Ph.D. (through June 2014), Cindy L. Vnencak-Jones, Ph.D.

Suggested Citation: Seegmiller, A., M. Jagasia, S. Wheeler, C. Vnencak-Jones. 2014. MLL-MLLT3 Fusion Gene in Acute Myeloid Leukemia. My Cancer Genome https://www.padiracinnovation.org/content/disease/acute-myeloid-leukemia/mll-mllt3/ (Updated April 11).

Last Updated: April 11, 2014

MLL-MLLT3 t(9;11)(p22;q23) Translocation in Acute Myeloid Leukemia

Properties
Location of translocation Chromosomal rearrangements involving the MLLT3 gene on 9p22 and the MLL gene on 11q23
Frequency of all 11q rearrangements in AML 1% (Grimwade et al. 2010)
Implications for Targeted Therapeutics
Response to FLT3 inhibitors Currently no role for MLL-MLLT3 in predicting response
Response to MEK inhibitors Currently no role for MLL-MLLT3 in predicting response
Response to JAK2 inhibitors Currently no role for MLL-MLLT3​ in predicting response
Response to DOT1L inhibitors Unknown at this timea

The MLL-MLLT3 gene fusion created by the t(9;11)(p22;q23) translocation is associated with intermediate prognosis in AML (NCCN 2012). The official symbol for MLL is KMT2A. MLLT3 is also known as AF9.

a In preclinical studies, MLL rearrangements were sensitive to DOT1L inhibitors such as EPZ004777 and EPZ-5676; DOT1L inhibitors have now entered clinical development (Basavapathruni et al. 2012; Chen et al. 2013; Daigle et al. 2011; Yu et al. 2012). ​

​​​​​

Contributors: Adam Seegmiller, M.D., Ph.D., Madan Jagasia, M.B.B.S., M.S.

Suggested Citation: Seegmiller, A., M. Jagasia. 2014. MLL-MLLT3 t(9;11)(p22;q23) Translocation in Acute Myeloid Leukemia. My Cancer Genome https://www.padiracinnovation.org/content/disease/acute-myeloid-leukemia/mll-mllt3/254/ (Updated April 11).

Last Updated: April 11, 2014

My Cancer Genome has released its new and improved cancer clinical trials search tool on our beta website. Please visit beta.padiracinnovation.org to check it out!

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.